Close Menu

NEW YORK (GenomeWeb) – Blood-based cancer detection firm Thrive Earlier Detection announced its launch today, supported by a $110 million financing round.

The Cambridge, Massachusetts-based firm plans to commercialize a circulating tumor DNA and protein testing method initially developed at Johns Hopkins University and currently being validated in a 10,000-person trial with Pennsylvania's Gesinger Health system.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.